
Quarterly report 2025-Q2
added 07-31-2025
Envista Holdings Corporation Financial Statements 2011-2025 | NVST
Annual Financial Statements Envista Holdings Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
3.68 B | 3.75 B | 6.42 B | 7.74 B | 6.15 B | 4.25 B | - | - | - | - | - | - | - | - |
Shares |
172 M | 167 M | 163 M | 161 M | 160 M | 136 M | - | - | - | - | - | - | - | - |
Historical Prices |
21.4 | 22.5 | 39.4 | 48 | 38.5 | 25.4 | - | - | - | - | - | - | - | - |
Net Income |
-1.12 B | -100 M | 243 M | 340 M | 33.3 M | 218 M | 231 M | 301 M | 272 M | - | - | - | - | - |
Revenue |
2.51 B | 2.57 B | 2.57 B | 2.51 B | 1.93 B | 2.75 B | 2.84 B | 2.81 B | 2.79 B | - | - | - | - | - |
Cost of Revenue |
1.14 B | 1.13 B | 1.09 B | 1.08 B | 874 M | 936 M | 1.24 B | 1.19 B | - | - | - | - | - | - |
Gross Profit |
1.37 B | 1.44 B | 1.47 B | 1.43 B | 1.05 B | 1.51 B | 1.6 B | 1.62 B | 1.6 B | - | - | - | - | - |
Operating Income |
-1.04 B | 31.5 M | 319 M | 306 M | 43.5 M | 236 M | 298 M | 387 M | - | - | - | - | - | - |
Interest Expense |
-100 K | -23 M | 3.1 M | 54.1 M | 62.5 M | 3.5 M | - | - | - | - | - | - | - | - |
EBITDA |
-915 M | 167 M | 457 M | 424 M | 165 M | 446 M | 428 M | 508 M | 530 M | - | - | - | - | - |
Operating Expenses |
2.27 B | 2.18 B | 2.13 B | - | - | 1.24 B | 1.3 B | 1.23 B | 1.2 B | - | - | - | - | - |
General and Administrative Expenses |
1.16 B | 1.06 B | 1.06 B | 1.02 B | 925 M | 1.08 B | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Envista Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
169 M | 172 M | 172 M | 172 M | 172 M | 172 M | 172 M | 168 M | 164 M | 164 M | 163 M | 163 M | 163 M | 162 M | 162 M | 162 M | 161 M | 160 M | 160 M | 160 M | 160 M | 159 M | 159 M | 131 M | 128 M | 128 M | 100 | 128 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
26.4 M | 18 M | - | 8.2 M | -1.15 B | 23.6 M | - | 21.5 M | 51.9 M | 43.8 M | - | 47.6 M | 47.1 M | 74.9 M | - | 92.9 M | 90.1 M | 71.7 M | 108 M | 35.6 M | -93.5 M | -17.2 M | 56.1 M | 62.1 M | 61.5 M | 37.9 M | 51.2 M | 64.1 M | 78.8 M | 36.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
682 M | 617 M | - | 601 M | 633 M | 624 M | - | 631 M | 662 M | 627 M | - | 631 M | 646 M | 631 M | 652 M | 607 M | 637 M | 613 M | 616 M | 547 M | 309 M | 456 M | 720 M | 659 M | 712 M | 660 M | 759 M | 680 M | 733 M | 673 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
312 M | 281 M | - | 284 M | 306 M | 267 M | - | 268 M | 284 M | 264 M | - | 266 M | 276 M | 257 M | - | 251 M | 328 M | 254 M | - | 239 M | 212 M | 269 M | - | 292 M | 318 M | 297 M | - | 299 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
370 M | 336 M | - | 317 M | 327 M | 356 M | - | 363 M | 379 M | 363 M | - | 365 M | 370 M | 374 M | 343 M | 356 M | 369 M | 358 M | 340 M | 308 M | 155 M | 251 M | 389 M | 367 M | 394 M | 363 M | 422 M | 381 M | 423 M | 376 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
46.3 M | 39 M | - | 20.9 M | -1.15 B | 48.1 M | - | 83.3 M | 78.9 M | 72.1 M | - | 74.5 M | 65.2 M | 91.5 M | - | 81.7 M | 98.5 M | 95.1 M | - | 61.6 M | -108 M | -25 M | - | 78.7 M | 75.9 M | 44.9 M | - | 81.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
2.4 M | -700 K | - | 600 K | -1.1 M | 100 K | - | -32.1 M | 7.1 M | 16.7 M | - | 11.6 M | 6.4 M | 5.9 M | - | 12 M | 13.6 M | 18 M | - | 23.4 M | 14.5 M | 3.3 M | - | 200 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
76.1 M | 66.9 M | - | - | -1.12 B | 80.2 M | - | - | - | 80.6 M | - | 98.4 M | 65.2 M | 99.3 M | - | 111 M | 98.5 M | 105 M | - | 93.1 M | -88.3 M | -15.5 M | - | 108 M | 95.7 M | 54.7 M | - | 110 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
295 M | 272 M | - | 271 M | 302 M | 285 M | - | 258 M | 273 M | 266 M | - | 264 M | 280 M | 258 M | - | 251 M | 283 M | 238 M | - | 227 M | 242 M | 269 M | - | 252 M | 278 M | 275 M | - | 257 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Envista Holdings Corporation NVSTFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Envista Holdings Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Baxter International
BAX
|
$ 18.99 | 0.48 % | $ 9.68 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 200.87 | 0.22 % | $ 57.8 B | ||
|
BioLife Solutions
BLFS
|
$ 24.43 | -1.81 % | $ 1.13 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 4.79 | 2.35 % | $ 96.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Repro Med Systems
KRMD
|
$ 5.75 | -1.88 % | $ 262 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
LeMaitre Vascular
LMAT
|
$ 83.51 | 0.18 % | $ 1.87 B | ||
|
Masimo Corporation
MASI
|
$ 138.1 | -2.25 % | $ 7.36 B | ||
|
ICU Medical
ICUI
|
$ 147.72 | 0.34 % | $ 3.6 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Merit Medical Systems
MMSI
|
$ 86.52 | -0.01 % | $ 5.04 B | ||
|
Alcon
ALC
|
$ 78.74 | -0.03 % | $ 40.4 B | ||
|
iRhythm Technologies
IRTC
|
$ 170.09 | 0.58 % | $ 5.31 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
AtriCure
ATRC
|
$ 42.08 | 1.62 % | $ 1.98 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
electroCore
ECOR
|
$ 4.81 | -0.21 % | $ 26.5 K | ||
|
Harvard Bioscience
HBIO
|
$ 0.76 | 1.78 % | $ 32.2 M | ||
|
InfuSystem Holdings
INFU
|
$ 9.24 | 0.33 % | $ 191 M | ||
|
AngioDynamics
ANGO
|
$ 13.12 | -2.42 % | $ 536 M | ||
|
The Cooper Companies
COO
|
$ 81.82 | -0.36 % | $ 16.3 B | ||
|
Predictive Oncology
POAI
|
$ 5.95 | 0.51 % | $ 32.4 M | ||
|
Glaukos Corporation
GKOS
|
$ 109.57 | 0.31 % | $ 5.31 B | ||
|
Haemonetics Corporation
HAE
|
$ 83.2 | -1.49 % | $ 4.19 B | ||
|
Repligen Corporation
RGEN
|
$ 156.65 | -3.1 % | $ 8.73 M | ||
|
OraSure Technologies
OSUR
|
$ 2.52 | -2.14 % | $ 188 M | ||
|
Intuitive Surgical
ISRG
|
$ 541.3 | -1.11 % | $ 192 B | ||
|
Nephros
NEPH
|
$ 5.08 | 2.24 % | $ 52.8 M | ||
|
Microbot Medical
MBOT
|
$ 2.43 | 2.21 % | $ 24.8 M | ||
|
STAAR Surgical Company
STAA
|
$ 24.16 | -2.11 % | $ 1.19 B | ||
|
Milestone Scientific
MLSS
|
$ 0.39 | 9.69 % | $ 31.1 M | ||
|
ResMed
RMD
|
$ 250.7 | -0.67 % | $ 36.6 B | ||
|
Stereotaxis
STXS
|
$ 2.38 | -1.45 % | $ 192 M | ||
|
STERIS plc
STE
|
$ 251.01 | -0.59 % | $ 24.7 B | ||
|
Pro-Dex
PDEX
|
$ 43.83 | 0.6 % | $ 144 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.26 | 3.71 % | $ 685 M | ||
|
Utah Medical Products
UTMD
|
$ 57.99 | 0.5 % | $ 210 M | ||
|
West Pharmaceutical Services
WST
|
$ 266.92 | -2.06 % | $ 19.5 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.59 | -0.13 % | $ 2.36 B | ||
|
Retractable Technologies
RVP
|
$ 0.83 | -0.31 % | $ 24.8 M | ||
|
Teleflex Incorporated
TFX
|
$ 125.81 | -1.13 % | $ 5.89 B |